CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a company specializing in treatments for nonalcoholic steatohepatitis (NASH), has upsized its public offering to $600 million, the firm announced Monday. The offering, originally set at $500 million, was increased by $100 million following strong investor interest. The company is offering 750,000 shares of common stock at $260...
On Tuesday, Baird initiated coverage on Alkermes stock (NASDAQ:ALKS), a biopharmaceutical company, with an Outperform rating and a price target of $37.00. The firm\'s analyst cited the company\'s solid financial guidance and promising pipeline as the basis for the positive outlook. Alkermes is projected to generate revenue between $1.5 billion and $1.6 billion for the...
Tuesday, Baird initiated coverage on shares of Axsome Therapeutics (NASDAQ:AXSM), assigning the stock an Outperform rating and setting a price target of $108.00. The firm has expressed confidence in the company\'s upcoming clinical trial results, particularly for its AXS-05 drug, which is currently in phase 3 trials for Alzheimer\'s disease agitation, expected in the second...
TEANECK, N.J. - Cognizant Technology Solutions Corp. (NASDAQ:CTSH) has announced a collaboration with NVIDIA Corporation (NASDAQ:NVDA) to enhance drug discovery in the life sciences sector using NVIDIA\'s BioNeMo generative AI platform. This initiative aims to improve the productivity of the drug development process and accelerate the introduction of new treatments to the market. Generative AI...
On Tuesday, KeyBanc initiated coverage on Atlassian (NASDAQ:TEAM) Corporation stock (NASDAQ:TEAM), assigning a Sector Weight rating. The firm highlighted Atlassian\'s strong position in the developer collaboration market, particularly with its Jira Software and Confluence products. KeyBanc sees a long-term growth opportunity for Atlassian as it transitions from data center (DC) to cloud-based services and expands...
Tuesday - KeyBanc Capital Markets has initiated coverage on GitLab Inc (NASDAQ:GTLB), assigning an Overweight rating with a price target of $70.00 for the shares. The firm\'s analysis suggests that GitLab, a company that operates as an independent DevSecOps platform, is poised for sustained mid-20% growth. This projection is based on the current stable-to-improving spending...
By Kevin Buckland TOKYO (Reuters) -The yen weakened and Japanese government bond yields fell after the Bank of Japan on Tuesday announced an exit from years of ultra-easy monetary policies, marking a historic shift from a decades-long fight against deflation. The Nikkei share average rose, reversing morning losses, following volatile trading immediately after the central...
On Tuesday, Guggenheim initiated coverage on DXC Technology stock (NYSE: NYSE:DXC), assigning a Neutral rating. The firm\'s analysis pointed to the challenges faced by the new management team, which has taken over an organization experiencing secular declines. The report acknowledged the potential for improvement under the new leadership but noted that such turnarounds are typically...
Tuesday, Guggenheim initiated coverage on Perficient stock (NASDAQ:PRFT), a digital consultancy firm, with a Neutral rating and a price target of $65.00. The firm recognized the company\'s high-value consulting-led approach and potential for margin expansion as it shifts more work offshore. The analyst noted that while Perficient\'s strategy for margin growth through a mix-shift in...
On Tuesday, Infosys Technologies (NYSE:NS:INFY) received a new stock coverage from Guggenheim, starting with a Neutral rating and a price target set at $20.00. The firm\'s decision is based on a balanced risk-reward scenario, as indicated by their analyst. The analysis highlights that the rationale behind the Neutral rating is Infosys\' potential for large deal...